Results 51 to 60 of about 5,702,542 (372)

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics

Blood Cancer Journal, 2023
Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed.
Daisuke Ogiya, Zuzana Chyra, Sigitas J. Verselis, Morgan O’Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia   +14 more
doaj   +1 more source

MULTIPLE MYELOMA [PDF]

JAMA: The Journal of the American Medical Association, 1922
n ...
openaire   +2 more sources

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2016
BACKGROUND Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination
A. Palumbo, A. Chanan-Khan, K. Weisel, A. Nooka, T. Masszi, M. Beksaç, I. Spicka, V. Hungria, M. Munder, M. Mateos, T. Mark, M. Qi, J. Schecter, H. Amin, X. Qin, W. Deraedt, T. Ahmadi, A. Spencer, P. Sonneveld   +18 more
semanticscholar   +1 more source

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Cancers, 2020
Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors and monoclonal antibodies.
Vanessa Pinto, Rui Bergantim, H. Caires, H. Seca, J. Guimarães, M. Vasconcelos   +5 more
semanticscholar   +1 more source

Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract

Cancer Communications, Volume 42, Issue 12, Page 1367-1386, December 2022., 2022
Abstract Background Neuroendocrine carcinomas of the gastrointestinal tract (GI‐NECs) remain a disease of grim prognosis with limited therapeutic options. Their molecular characteristics are still undefined. This study aimed to explore the underlying genetic basis and heterogeneity of GI‐NECs.
Huanwen Wu, Zicheng Yu, Yueping Liu, Lei Guo, Lianghong Teng, Lingchuan Guo, Li Liang, Jing Wang, Jie Gao, Ruiyu Li, Ling Yang, Xiu Nie, Dan Su, Zhiyong Liang   +13 more
wiley   +1 more source

Segmentation of Multiple Myeloma Plasma Cells in Microscopy Images with Noisy Labels [PDF]

arXiv, 2021
A key component towards an improved and fast cancer diagnosis is the development of computer-assisted tools. In this article, we present the solution that won the SegPC-2021 competition for the segmentation of multiple myeloma plasma cells in microscopy images.
arxiv  

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2016
BACKGROUND Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma.
M. Dimopoulos, A. Oriol, H. Nahi, J. San-Miguel, N. Bahlis, S. Usmani, N. Rabin, R. Orlowski, M. Komarnicki, Kenshi Suzuki, T. Plesner, S. Yoon, D. Ben Yehuda, P. Richardson, H. Goldschmidt, D. Reece, S. Lisby, N. Khokhar, L. O’Rourke, Christopher Chiu, X. Qin, Mary E. Guckert, T. Ahmadi, P. Moreau   +23 more
semanticscholar   +1 more source

BCMA-targeted immunotherapy for multiple myeloma

Journal of Hematology & Oncology, 2020
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen
Bo Yu, Tianbo Jiang, Delong Liu
semanticscholar   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

Blood Cancer Journal
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood.
Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, Tsuyoshi Fukushima, Ryan S. Han, Rajib Shome, Kiyosumi Ochi, Cristina Panaroni, Keertik Fulzele, Farah Rexha, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, David T. Scadden, Noopur S. Raje   +14 more
doaj   +1 more source